Background
==========

With the obvious increasing prevalence and mortality rate, cancer has become one of the primary causes of morbidity and mortality \[[@b1-medscimonit-21-2505]\]. The underlying mechanisms of the tumorigenesis are obscure because of the involvement of multiple risk factors containing complicated gene-gene and gene-environment interactions \[[@b2-medscimonit-21-2505]\]. Many studies have demonstrated that the occurrence of cancers may be related to inflammation, and that cytokines are associated with individual susceptibility to cancers \[[@b3-medscimonit-21-2505]\].

Cytokine-mediated immunity plays a critical role in the tumorigenesis \[[@b4-medscimonit-21-2505]\]. IL-27 is included in the cytokines of IL-12 family. It is located on chromosome 16 (16p11) and comprises 2 subunits-Epstein-Barr virus-induced gene 3 (EBI3) and p28, which is a recently discovered IL-12p35-related polypeptide \[[@b5-medscimonit-21-2505]\]. IL-27 is mainly secreted by antigen-presenting cells. It was described as a pro-inflammatory cytokine that enhances T helper (Th) 1 responses, cytotoxic T lymphocytes (CTLs) maturation, natural killer (NK) cells stimulation, and secretion of interferon-γ (IFN-γ) \[[@b5-medscimonit-21-2505]\]. Research shows that IL-27 can impair tumor progression by CD8+ T cells with promoted CTL reaction, regardless of tumor immunogenicity \[[@b6-medscimonit-21-2505]\]. Additionally, IL-12 inhibits neoangiogenesis in tumors by stimulation of IFN-γ-inducible protein-10 (IP-10) \[[@b7-medscimonit-21-2505]\].

In view of the association of *IL-27* polymorphisms and susceptibility to cancer, some previous case-control studies were conducted among Chinese population \[[@b8-medscimonit-21-2505]--[@b13-medscimonit-21-2505]\]. However, the conclusions were inconsistent and inconclusive. In 2014, Hu et al. \[[@b14-medscimonit-21-2505]\] conducted a meta-analysis of 6 case-control studies and concluded that *IL-27* rs153109 polymorphism was associated with cancer susceptibility in Chinese, a result consistent with another meta-analysis of 8 case-control studies by Xu et al. \[[@b15-medscimonit-21-2505]\] that *IL-27-*964A/G (rs153109) polymorphism might enhance cancer susceptibility. Using more recent studies, we conducted an updated meta-analysis to obtain a more precise evaluation of the relevance of *IL-27* polymorphisms (rs153109, rs17855750, and rs181206) and cancer susceptibility.

Material and Methods
====================

Literature search strategy
--------------------------

We conducted a comprehensive literature search in PubMed, Web of Science, Google Scholar, CNKI (Chinese National Knowledge Infrastructure), and Wanfang databases to find all eligible case-control studies up to June 11, 2015 on the association between polymorphisms of *IL-27* (rs153109, rs17855750 and rs181206) and cancer susceptibility by applying the searching terms: ("interleukin-27" OR "*IL-27*") and ("mutation" OR "polymorphism" OR "variant") and ("cancer" OR "malignancy" OR "carcinoma" OR "tumour" OR "neoplasm") without language restriction. In addition, we checked the reference lists of all the eligible publications or the relevant reviews for additional studies.

Selection criteria
------------------

The studies enrolled in the current meta-analysis had to satisfy the following criteria: (a) studies that assessed the relevance between the polymorphisms in *IL-27* and cancer susceptibility; (b) studies designed as case-control; (c) we can obtain specific genotype frequency of all the cases and controls or they can be obtained from the available data. We excluded studies which were: (a) case-only studies, reviews, comments, and case reports; (b) studies without the raw statistics of the polymorphisms of *IL-27*; (c) publications that were repetitive; (d) studies focused on animals.

Data extraction
---------------

The following details were recorded from each study by 3 investigators (Meng Zhang, Xiuxiu Tan, and Junjie Huang): the name of the first author, year published, ethnicity of the case-control studies, source of controls, genotyping method, the number of cases and controls, and the P value of the HWE in control groups. Any disagreements were discussed by the 3 authors until a consensus was reached.

Statistical analysis
--------------------

We assessed the association between *IL-27* polymorphisms and cancer susceptibility by OR and 95% CI. A total of 5 different ORs were calculated: allele contrast model (B *vs.* A), dominant model (BB+AB *vs.* AA), recessive model (BB *vs.* AB+AA), heterozygote comparison (AB *vs.* AA), and homozygote comparison (BB *vs.* AB) (AA, homozygotes for the common allele; AB, heterozygotes; BB, homozygotes for the rare allele). We conducted a χ^2^-test-based Q statistic test to evaluate the heterogeneity within the case-control studies \[[@b16-medscimonit-21-2505]\]. If the Q test (P\>0.1) suggested homogeneity across studies, we selected the fixed-effects model \[[@b17-medscimonit-21-2505]\]; otherwise, the random-effects model was used \[[@b18-medscimonit-21-2505]\]. In addition, we further quantified the heterogeneity effect by I^2^ test (I^2^\<25%: no heterogeneity; I^2^=25--50%: moderate heterogeneity; I^2^=50--75%: high heterogeneity, I^2^\>75%: extreme high heterogeneity) \[[@b19-medscimonit-21-2505]\]. P values of the HWE for control groups were tested by χ^2^ test. Stratification analyses on tumor type and genotyping method were conducted. If any cancer type totals no more than 2 studies, we included it into the "other cancers" group. Sensitivity analyses were used to calculate the stability of the results by removing a single case-control study from the enrolled pooled data to detect the influence of that data set on the pooled ORs. Finally, we used Begg's funnel plot and Egger's regression test to evaluate the potential publication bias \[[@b20-medscimonit-21-2505], [@b21-medscimonit-21-2505]\]. P\<0.05 was considered as statistically significant. We used STATA 12.0 (Stata Corporation, College Station, Texas) to conduct all statistical analyses.

Results
=======

Study characteristics
---------------------

As presented in [Figure 1](#f1-medscimonit-21-2505){ref-type="fig"}, after a systematic literature search in the databases, 46 potential relevant studies on the association between *IL-27* polymorphisms and cancer were identified. Nevertheless, of them, 34 were unqualified in that some were based on case-only design, some were not polymorphism studies and the others were not concerning the susceptibility of cancer. In the end, a total of 12 publications with 27 independent case-control studies comprising of 7,570 cases and 9,839 controls were concerning the associations of *IL-27* polymorphisms and cancer susceptibility. The characteristics of enrolled studies were presented in [Table 1](#t1-medscimonit-21-2505){ref-type="table"} \[[@b8-medscimonit-21-2505]--[@b13-medscimonit-21-2505],[@b22-medscimonit-21-2505]--[@b27-medscimonit-21-2505]\]. The genotype distributions of the three polymorphisms and the genotyping method of the enrolled studies were retrieved scrupulously, and the controls were selected from non-cancer populations. Additionally, there were three case-control studies deviated from HWE \[[@b13-medscimonit-21-2505],[@b23-medscimonit-21-2505]\].

Meta-analysis
-------------

The results of the meta-analysis for the association of *IL-27* polymorphisms (rs17855750, rs181206 and rs153109) with susceptibility to cancer are presented in [Table 2](#t2-medscimonit-21-2505){ref-type="table"}. Obvious heterogeneity was identified in *IL-27* rs17855750 polymorphism (GG *vs.* TT: P~heterogeneity~=0.036, I^2^=61.2% and GG *vs.* GT+TT: P~heterogeneity~=0.046, I^2^=58.7%) and rs153109 polymorphism under all 5 genetic models (G *vs.* A: P~heterogeneity~=0.003, I^2^=35.5%; GG *vs.* AA: P~heterogeneity~=0.038, I^2^=20.4%; GA *vs.* AA: P~heterogeneity~=0.047, I^2^=18.8%; GG+GA *vs.* AA: P~heterogeneity~=0.006, I^2^=32.6%; GG *vs.* GA+AA: P~heterogeneity~=0.038, I^2^=4.9%) ([Table 2](#t2-medscimonit-21-2505){ref-type="table"}). Therefore, we chose the random-effects model to generate wider CIs in these genetic models.

The present work identified that rs17855750 polymorphism of *IL-27* was significantly associated with cancer susceptibility (G *vs.* T: OR=1.177, 95%CI=1.304--1.341, P~heterogeneity~=0.156, [Figure 2A](#f2-medscimonit-21-2505){ref-type="fig"}; GG+GT *vs.* TT: OR=1.156, 95%CI=1.005--1.329, P~heterogeneity~=0.410, [Figure 2B](#f2-medscimonit-21-2505){ref-type="fig"}), particularly for bladder cancer (GG *vs.* TT: OR=14.600, 95%CI=1.653--128.994, P~heterogeneity~=0.647; GG *vs.* GT+TT: OR=14.480, 95%CI=1.640--127.836, P~heterogeneity~=0.658). Nevertheless, no association was identified between *IL-27* rs153109 and rs181206 polymorphisms and cancer susceptibility. When a stratification analysis was performed by cancer type, we identified an increased susceptibility of bladder cancer in rs153109 polymorphism (GA *vs.* AA: OR=1.413, 95%CI=1.080--1.848, P~heterogeneit~y=0.725). Moreover, in the stratification analysis by genotyping method, we identified an increased susceptibility for PCR-RFLP group in rs17855750 polymorphism (G *vs.* T: OR=1.194, 95%CI=1.028--1.387, P~heterogeneity~=0.074; GG+GT *vs.* TT: OR=1.185, 95%CI=1.008--1.392, P~heterogeneity~=0.232), whereas a decreased susceptibility was identified in rs153109 polymorphism (GG *vs.* AA: OR=0.943, 95%CI=0.890--1.000, P~heterogeneity~=0.094) ([Table 2](#t2-medscimonit-21-2505){ref-type="table"}).

Sensitivity analyses and publication bias
-----------------------------------------

We performed sensitivity analysis by omitting each study sequentially, suggesting that the results for the overall population were statistically robust and reliable ([Figure 3A--3C](#f3-medscimonit-21-2505){ref-type="fig"}). Egger's test and Begg's funnel plot were performed to examine the publication bias risk in our research. No publication bias was identified (rs153109: G *vs.* A: P=0.300 for Begg's test, P=0.112 for Egger's test, [Figure 4A](#f4-medscimonit-21-2505){ref-type="fig"}; rs181206: C *vs.* T: P=0.133 for Begg's test, P=0.252 for Egger's test; [Figure 4B](#f4-medscimonit-21-2505){ref-type="fig"}; rs17855750: G *vs.* T: P=0.283 for Begg's test, P=0.322 for Egger's test; [Figure 4C](#f4-medscimonit-21-2505){ref-type="fig"}).

Discussion
==========

Interleukin-27 is a newly discovered member of the IL-12 family, which is regarded as a mediator of naive T cell proliferation, and an inducer of IFN-g secretion, specifically in synergy with IL-12 \[[@b28-medscimonit-21-2505]\]. Recently, Chiyo et al. \[[@b29-medscimonit-21-2505]\] investigated the antitumor ability of IL-27 against a murine tumour model and observed that IL-27 could induce tumour-specific antitumor activity. The relationship between *IL-27* polymorphisms and cancer susceptibility had been investigated in recently published case-control studies, but conflicting results were reported. Meta-analysis is regarded as a crucial method to accurately define the influence of specific genetic polymorphisms on cancer susceptibility. After searching the databases, 2 meta-analyses were found focussing on the relevance of the *IL-27* polymorphisms and cancer susceptibility \[[@b14-medscimonit-21-2505],[@b15-medscimonit-21-2505]\]. In 2014, Hu et al. \[[@b14-medscimonit-21-2505]\] conducted a meta-analysis and concluded that *IL-27* rs153109 polymorphism was associated with cancer susceptibility in Chinese, whereas the rs17855750 and rs181206 polymorphisms were not. The results were consistent with another meta-analysis conducted by Xu et al. \[[@b15-medscimonit-21-2505]\], which reported that *IL-27* rs153109 polymorphism might enhance cancer susceptibility. Additionally, their results also demonstrated that *IL-27* rs153109 polymorphism increased colorectal cancer susceptibility. However, several limitations in both analyses were obvious. First, the number of eligible published studies used was limited to a total of 6, with 1684 patients and 1837 controls. Second, there were 8 case-control studies, including 2044 cancer cases and 2197 controls focussing only on a single *IL-27* polymorphism. Therefore, we performed the current meta-analysis to comprehensively elucidate the effects of *IL-27* polymorphisms (rs153109, rs17855750 and rs181206) in a total of 12 publications, including 27 case-control studies comprising 7570 patients and 9839 controls. Interestingly, the results were inconsistent with previous studies. Except for *IL-27* rs17855750 polymorphism, there was no evident relationship between the *IL-27* rs153109 and rs17855750 polymorphisms and cancer susceptibility. In addition, when we performed a stratification analysis by cancer type, an increased susceptibility to bladder cancer in rs153109 polymorphism was identified.

Nevertheless, there exist several drawbacks in our meta-analysis. Stratifications may be introduced by the combination of genetic studies on various cancers in the meta-analysis. The results of *IL-27* polymorphisms on cancer susceptibility might be affected by several complicated factors, such as age, sex, ethnicity, source of controls, and matching criteria when we lack the original data. Additionally, only papers published in a limited number of databases were searched, and some studies might have been missed; therefore, the eligible case-control samples included into the current meta-analysis were insufficient. Thirdly, all the studies were conducted in Chinese, and no research in whites or Africans was identified.

Conclusions
===========

This meta-analysis illustrated that *IL-27* rs17855750 polymorphism enhanced cancer susceptibility in a Chinese population, and an increased susceptibility of bladder cancer was identified in rs153109 polymorphism when a stratification analysis was performed by cancer type. Further well-planned studies on these variants are warranted to discover the mechanisms of *IL-27* polymorphisms in the tumorigenesis of these cancers.
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![(**A**) OR estimates with the corresponding 95% CI for the association of *IL-27* rs17855750 polymorphism with overall cancer risk (G *vs.* T). The sizes of the squares represent the weighting of included studies; OR: odds ratio; CI: confidence interval. (**B**) OR estimates with the corresponding 95% CI for the association of *IL-27* rs17855750 polymorphism with overall cancer risk (GG+GT *vs.* TT). The sizes of the squares represent the weighting of included studies; OR: odds ratio; CI: confidence interval.](medscimonit-21-2505-g002){#f2-medscimonit-21-2505}

![(**A**) Sensitivity analysis of overall OR coefficients for *IL-27* rs153109 polymorphism (G *vs.* A). Results were calculated by omitting each study in turn. The 2 ends of the dotted lines represent the 95%CI. (**B**) Sensitivity analysis of overall OR coefficients for *IL-27* rs181206 polymorphism (C *vs.* T). Results were calculated by omitting each study in turn. The 2 ends of the dotted lines represent the 95%CI. (**C**) Sensitivity analysis of overall OR coefficients for *IL-27* rs17855750 polymorphism (G *vs.* T). Results were calculated by omitting each study in turn. The 2 ends of the dotted lines represent the 95%CI.](medscimonit-21-2505-g003){#f3-medscimonit-21-2505}

![(**A**) Publication bias in studies of the association between the *IL-27* rs153109 polymorphism and cancer susceptibility assessed by Begg's funnel plot and Egger's test (G *vs.* A). Log (OR): the natural logarithm of the odds ratio. (**B**) Publication bias in studies of the association between the *IL-27* rs181206 polymorphism and cancer risk assessed by Begg's funnel plot and Egger's test (C *vs.* T). Log (OR): the natural logarithm of the odds ratio. (**C**) Publication bias in studies of the association between the *IL-27* rs17855750 polymorphism and cancer susceptibility assessed by Begg's funnel plot and Egger's test (G *vs.* T). Log (OR): the natural logarithm of the odds ratio.](medscimonit-21-2505-g004){#f4-medscimonit-21-2505}

###### 

Characteristics of the enrolled studies.

  SNP          First author   Year   Source of Control   Country   Genotyping method   Cancer type    Case   Control                         
  ------------ -------------- ------ ------------------- --------- ------------------- -------------- ------ --------- ---- ----- ----- ---- -----------
  RS153109     Wei et al.     2009   HB                  Chinese   PCR-RFLP            NPC            119    150       33   113   161   36   0.060
               Zhao et al.    2009   HB                  Chinese   PCR-RFLP            Glioma         79     101       30   81    112   27   0.215
               Peng et al.    2013   HB                  Chinese   PCR-RFLP            HCC            38     48        21   40    46    19   0.371
               Zhang et al.   2015   HB                  Chinese   PCR-RFLP            PTC            287    309       68   332   399   96   0.147
               Pan et al.     2012   HB                  Chinese   PCR-RFLP            NPC            90     78        22   85    87    28   0.453
               Tao et al.     2012   HB                  Chinese   PCR-RFLP            ESC            163    205       58   162   219   51   0.075
               Zhang et al.   2014   HB                  Chinese   PCR-RFLP            EOC            85     103       41   161   124   35   0.139
               Guo et al.     2012   HB                  Chinese   PCR-RFLP            CRC            53     84        33   75    66    19   0.449
               Huang et al.   2012   HB                  Chinese   PCR-RFLP            CRC            151    213       46   183   222   45   0.059
               Zhang et al.   2014   HB                  Chinese   PCR-RFLP            BRC            143    156       27   185   223   52   0.213
               Tang et al.    2014   HB                  Chinese   PCR                 Osteosarcoma   56     85        19   100   124   26   0.167
               Zhou et al.    2015   HB                  Chinese   PCR                 BC             66     87        23   229   204   66   0.058
               Zhou et al.    2015   HB                  Chinese   PCR                 BC             61     73        22   229   204   66   0.058
  RS17855750   Wei et al.     2009   HB                  Chinese   PCR-RFLP            NPC            247    55        0    259   51    0    0.115
               Zhao et al.    2009   HB                  Chinese   PCR-RFLP            Glioma         169    41        0    185   35    0    0.200
               Peng et al.    2013   HB                  Chinese   PCR-RFLP            HCC            83     21        3    72    28    5    0.304
               Zhang et al.   2014   HB                  Chinese   PCR-RFLP            OC             170    51        8    267   53    0    0.106
               Tao et al.     2012   HB                  Chinese   PCR-RFLP            ESC            345    81        0    355   77    0    **0.042**
               Huang et al.   2012   HB                  Chinese   PCR-RFLP            CRC            341    69        0    382   68    0    0.083
               Guo et al.     2012   HB                  Chinese   PCR-RFLP            CRC            120    41        9    122   33    5    0.151
               Tang et al.    2014   HB                  Chinese   PCR                 Osteosarcoma   132    28        0    205   45    0    0.118
               Zhou et al.    2015   HB                  Chinese   PCR                 BC             149    26        1    421   78    0    0.058
               Zhou et al.    2015   HB                  Chinese   PCR                 BC             126    27        3    421   78    0    0.058
  RS181206     Wei et al.     2009   HB                  Chinese   PCR-RFLP            NPC            241    61        0    253   57    0    0.075
               Zhao et al.    2009   HB                  Chinese   PCR-RFLP            Glioma         166    44        0    182   38    0    0.161
               Pan et al.     2012   HB                  Chinese   PCR-RFLP            NPC            157    33        0    158   42    0    0.097
               Tao et al.     2012   HB                  Chinese   PCR-RFLP            ESC            335    91        0    354   78    0    **0.039**
               Huang et al.   2012   HB                  Chinese   PCR-RFLP            CRC            331    79        0    373   77    0    **0.047**
               Tang et al.    2014   HB                  Chinese   PCR                 Osteosarcoma   131    29        0    207   43    0    0.137

NPC -- nasopharyngeal carcinoma; HCC -- hepatocellular carcinoma; PTC -- papillary thyroid cancer; CRC -- colorectal cancer; BC -- bladder cancer; ESC -- esophageal cancer; EOC -- epithelial ovarian cancer; BRC -- breast cancer; PCR-RFLP -- polymerase chain reaction-restriction fragment length polymorphism; HWE -- Hardy-Weinberg equilibrium; H-B: hospital based.

###### 

Results of meta-analysis for the polymorphisms in *IL-27* and cancer risk.

  Variables (rs17855750)     Case/Control        G *vs.* T                                                                  GG *vs.* TT                  GT *vs.* TT                                                                                                                                                                                                              
  -------------------------- ------------------- -------------------------------------------------------------------------- ---------------------------- ------------------------- ------------------------------------------------------------------------------ ----------------- ---------- -------------------------------------------------------------------------- ------- ------
  Total                                          1.177 (1.034--1.341)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.156                        31.5                      3.529 (0.803--15.515)                                                          0.036             61.2       1.120 (0.972--1.290)                                                       0.747   0.0
   Bladder cancer                                1.196 (0.877--1.630)                                                       0.322                        0.0                       14.600 (1.653--128.994)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}    0.647             0.0        1.042 (0.742--1.464)                                                               
   Colorectal cancer                             1.211 (0.925--1.586)                                                       0.511                        0.0                       1.830 (0.596--5.619)                                                           --                --         1.177 (0.872--1.588)                                                       0.746   0.0
  Genotyping method                                                                                                         0.554                        0.0                                                                                                                                                                                                                      
   PCR-RFLP                                      1.194 (1.028--1.387)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.074                        47.9                      2.035 (0.356--11.628)                                                          0.037             69.6       1.155 (0.981--1.361)                                                       0.550   0.0
   PCR                                           1.125 (0.865--1.464)                                                       0.472                        0.0                       14.600 (1.653--128.994)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}    0.647             0.0        1.019 (0.766--1.354)                                                       0.815   0.0
                             **Case/ control**   **GG+GT** ***vs.*** **TT**                                                 **GG** ***vs.*** **GT+TT**                                                                                                                                                                                                                            
  **OR (95% CI)**            **P**^a^            **I^2^** **(%)**                                                           **OR (95% CI)**              **P**^a^                  **I^2^** **(%)**                                                                                                                                                                               
  Total                                          1.156 (1.005--1.329)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.410                        3.3                       3.413 (0.818--14.250)                                                          0.046             58.7                                                                                          
   Bladder cancer                                1.121 (0.804--1.563)                                                       0.421                        0.0                       14.480 (1.640--127.836)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}    0.658             0.0                                                                                           
   Colorectal cancer                             1.205 (0.899--1.615)                                                       0.602                        0.0                       1.733 (0.568--5.286)                                                           --                --                                                                                            
  Genotyping method                                                                                                                                                                                                                                                                                                                                                               
   PCR-RFLP                                      1.185 (1.008--1.392)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.232                        25.7%                     1.974 (0.380--10.249)                                                          0.051             66.4                                                                                          
   PCR                                           1.073 (0.811--1.420)                                                       0.645                        0.0%                      14.480 (1.640--127.8360)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.658             0.0                                                                                           
  **Variables (rs181206)**   **Case/ control**   **C** ***vs.*** **T**                                                      **CC** ***vs.*** **TT**      **CT** ***vs.*** **TT**                                                                                                                                                                                                  
  **OR (95% CI)**            **P**^a^            **I^2^** **(%)**                                                           **OR (95% CI)**              **P**^a^                  **I^2^** **(%)**                                                               **OR (95% CI)**   **P**^a^   **I^2^** **(%)**                                                                   
  Total                                          1.110 (0.947--1.302)                                                       0.823                        0.0%                      --                                                                             --                --         1.124 (0.950--1.330)                                                       0.784   0.0
   NPC                                           0.983 (0.730--1.322)                                                       0.314                        1.2%                      --                                                                             --                --         0.981 (0.716--1.342)                                                       0.287   11.8
  Genotyping method                                                                                                                                                                                                                                                                                                                                                               
   PCR-RFLP                                      1.116 (0.943--1.321)                                                       0.709                        0.0%                      --                                                                             --                --         1.131 (0.946--1.351)                                                       0.662   0.0
                             **Case/ control**   **CC+CT** ***vs.*** **TT**                                                 **CC** ***vs.*** **CT+TT**                                                                                                                                                                                                                            
  **OR (95% CI)**            **Pa**              **I2**                                                                     **OR (95% CI)**              **Pa**                    **I2**                                                                                                                                                                                         
  Total                                          1.124 (0.950--1.330)                                                       0.784                        0.0                       --                                                                             --                --                                                                                            
   NPC                                           0.981 (0.716--1.342)                                                       0.287                        11.8                      --                                                                             --                --                                                                                            
  Genotyping method                                                                                                                                                                                                                                                                                                                                                               
   PCR--RFLP                                     1.131 (0.946--1.351)                                                       0.662                        0.0                       --                                                                             --                --                                                                                            
  **Variables (rs153109)**   **Case/ control**   **G** ***vs.*** **A**                                                      **GG** ***vs.*** **AA**      **GG** ***vs.*** **AA**                                                                                                                                                                                                  
  **OR (95% CI)**            **P**^a^            **I^2^** **(%)**                                                           **OR (95% CI)**              **P**^a^                  **I^2^** **(%)**                                                               **OR (95% CI)**   **P**^a^   **I^2^** **(%)**                                                                   
  Total                      3526/4732           1.080 (0.972--1.201)                                                       0.003                        35.5                      1.137 (0.929--1.391)                                                           0.038             20.4       1.095 (0.961--1.249)                                                       0.047   18.8
  Cancer type                                                                                                                                                                                                                                                                                                                                                                     
   NPC                       492/510             0.895 (0.746--1.075)                                                       0.661                        0.0                       0.814 (0.540--1.226)                                                           0.706             0.0        0.870 (0.667--1.134)                                                       0.875   0.0
   Colorectal cancer         580/610             1.325 (0.911--1.927)                                                       0.044                        57.0                      1.671 (0.859--3.253)                                                           0.098             40.3       1.386 (0.910--2.110)                                                       0.123   33.5
   Bladder cancer            332/998             1.190 (0.991--1.428)                                                       0.948                        0.0                       1.230 (0.831--1.819)                                                           0.932             0.0        1.413 (1.080--1.848)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.725   0.0
  Genotyping method                                                                                                                                                                                                                                                                                                                                                               
   PCR--RFLP                 3034/3484           1.057 (0.928--1.205)                                                       0.001                        44.9                      0.943 (0.890--1.000)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}       0.094             27.9       1.035 (0.896--1.195)                                                       0.077   17.8
   PCR                       492/1248            1.178 (1.009--1.375)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.979                        0.0                       1.144 (0.899--1.456)                                                           0.792             0.0        1.357 (1.081--1.703)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.805   0.0
                             **Case/ control**   **GG+GA** ***vs.*** **AA**                                                 **GG** ***vs.*** **GA+AA**                                                                                                                                                                                                                            
  **OR (95% CI)**            **P**^a^            **I^2^** **(%)**                                                           **OR (95% CI)**              **P**^a^                  **I^2^** **(%)**                                                                                                                                                                               
  Total                      3526/4732           1.112 (0.963--1.283)                                                       0.006                        32.6                      1.064 (0.930--1.218)                                                           0.038             4.9                                                                                           
  Cancer type                                                                                                                                                                                                                                                                                                                                                                     
   NPC                       664/827             0.857 (0.666--1.104)                                                       0.786                        0.0                       0.878 (0.598--1.289)                                                           0.708             0.0                                                                                           
   Colorectal cancer         160/250             1.465 (0.897--2.393)                                                       0.786                        51.4                      1.328 (0.934--1.889)                                                           0.237             8.0                                                                                           
   Bladder cancer            492/510             1.368 (1.061--1.764)                                                       0.794                        0.0                       1.029 (0.715--1.481)                                                           0.812             0.0                                                                                           
  Genotyping method          210/220                                                                                                                                                                                                                                                                                                                                              
   PCR--RFLP                 426/432             1.061 (0.898--1.253)                                                       0.006                        37.2                      1.065 (0.917--1.237)                                                           0.175             8.6                                                                                           
   PCR                       229/320             1.331 (1.072--1.652)[\*](#tfn3-medscimonit-21-2505){ref-type="table-fn"}   0.890                        0.0                       1.061 (0.775--1.453)                                                           0.923             0.0                                                                                           

I^2^: 0--25, means no heterogeneity; 25--50, means modest heterogeneity; \>50, means high heterogeneity; P^a^: P value of Q test for heterogeneity test;

means statistically significant (P\<0.05).
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